Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Combinations of Pharmacologic Smoking Cessation Treatments

This study has been completed.
Sponsor:
Information provided by:
VA Office of Research and Development
ClinicalTrials.gov Identifier:
NCT00018187
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: May 2007
  Purpose
The purpose of this study is to test the effectiveness of a combination of the drugs bupropion and mecamylamine along with a nicotine patch as a therapy for smoking cessation.

Condition Intervention Phase
Smoking
Drug: Bupropion
Drug: Mecamylamine
Drug: Nicotine Patch
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Combinations of Pharmacologic Smoking Cessation Treatments

Resource links provided by NLM:


Further study details as provided by VA Office of Research and Development:

Study Start Date: November 1998
Estimated Study Completion Date: June 2001
  Eligibility

Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
Subjects must be a smoker between 20 and 40 years old, have smoked at least 20 cigarettes per day for at least 2 years, wish to stop smoking and be in good general health
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00018187

Locations
United States, California
VA Greater Los Angeles Healthcare System
Los Angeles, California, United States, 90073
Sponsors and Collaborators
VA Office of Research and Development
Investigators
OverallOfficial: Neil Hartman, M.D.
  More Information

ClinicalTrials.gov Identifier: NCT00018187     History of Changes
Other Study ID Numbers: ADRD-011-98S 
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by VA Office of Research and Development:
smoking cessation
bupropion
mecamylamine
nicotine

Additional relevant MeSH terms:
Nicotine
Mecamylamine
Bupropion
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Ganglionic Blockers
Nicotinic Antagonists
Cholinergic Antagonists
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Agents
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on December 06, 2016